Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

(2021) Kamal Abu Jabal et al.   Eurosurveillance

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

(2021) Merryn Voysey et al.   LANCET

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

(2021) Maria Prendecki et al.   LANCET

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases

(2021) Andreas Kronbichler et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

COVID-19 vaccination and antirheumatic therapy

(2021) Jack Arnold et al.   RHEUMATOLOGY

Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease

(2021) Tabitha Turner-Stokes et al.   Kidney International Reports

Risk factors for severe outcomes in patients with systemic vasculitis & COVID‐19: a bi‐national registry‐based cohort study

(2021) Matthew A Rutherford et al.   Arthritis & Rheumatology

American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases – Version 1

(2021) Jeffrey R Curtis et al.   Arthritis & Rheumatology

Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies

(2021) Aodhán Seán Breathnach et al.   JOURNAL OF INFECTION

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

(2020) Isabella Quinti et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover

(2020) Annarosa Soresina et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring

(2020) Meryl Waldman et al.   KIDNEY INTERNATIONAL

Correlates of protection against SARS-CoV-2 in rhesus macaques

(2020) Katherine McMahan et al.   NATURE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Methotrexate, Anti-Tumor Necrosis Factor α, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

(2013) Charlotte Hua et al.   ARTHRITIS CARE & RESEARCH

The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab

(2011) U. Arad et al.   VACCINE

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

(2009) Sander van Assen et al.   ARTHRITIS AND RHEUMATISM